Rocco Barazzoni1, Silvia Palmisano2, Gianluca Gortan Cappellari3, Michela Giuricin2, Elisa Moretti2, Pierandrea Vinci3, Annamaria Semolic3, Gianfranco Guarnieri3, Michela Zanetti3, Nicolò de Manzini2. 1. Internal Medicine, Department of Medical, Surgical and Health Sciences, University of Trieste, and Azienda Ospedaliera "Ospedali Riuniti," Trieste, Italy. Electronic address: barazzon@units.it. 2. General Surgery, Department of Medical, Surgical and Health Sciences, University of Trieste, and Azienda Ospedaliera "Ospedali Riuniti," Trieste, Italy. 3. Internal Medicine, Department of Medical, Surgical and Health Sciences, University of Trieste, and Azienda Ospedaliera "Ospedali Riuniti," Trieste, Italy.
Abstract
BACKGROUND: Systemic inflammation contributes to obesity-associated complications. The short pentraxin C-reactive protein (CRP) is a validated inflammatory marker, whereas long pentraxin-3 (PTX3) limits inflammation and is adaptively stimulated by proinflammatory cytokines in vitro. Severely obese (SO) patients (body mass index [BMI]>40] have the highest obesity-associated complications and increasingly undergo surgical treatment. SO-associated changes in plasma PTX3 and their interactions with systemic inflammation are, however, unknown. OBJECTIVE: We sought to determine potential alterations in plasma PTX3 and their associations with changes in inflammatory markers before and after weight loss induced by laparoscopic Roux-en-Y gastric bypass (LRYGB). SETTING: University hospital in Trieste, Italy. METHODS: Plasma PTX3, CRP, and cytokines, including tumor necrosis factor α and interleukin 6 were measured in (1) 24 individuals with severe, class III obesity (SO; age = 42 ± 1 yr, female/male = 18/6, BMI = 45 ± 1 kg/m(2)) before and 3, 6, and 12 months after LRYGB; and (2) age- and sex-matched normal-weight (N; n = 56, BMI = 22 ± .2 kg/m(2)) or class I obese individuals (O; n = 44, BMI = 31.2 ± .3 kg/m(2)). RESULTS: SO, but not O, had higher plasma PTX3 compared with N, associated with highest proinflammatory cytokines and CRP (P<.05 versus N-O). In all patients, plasma interleukin 6 and tumor necrosis factor α were associated positively with PTX3 (P<.05). Plasma CRP and proinflammatory cytokines declined during LRYGB-induced weight loss. In contrast, high PTX3 further increased and remained elevated (P<.05 versus basal). CONCLUSIONS: Obesity level and energy balance modulate interactions between PTX3 and systemic inflammation. Elevated PTX3 is a novel, potentially adaptive alteration associated with proinflammatory cytokines in SO. Their differential changes conversely suggest circulating PTX3 as a novel negative inflammatory marker in SO undergoing LRYGB-induced weight loss.
BACKGROUND: Systemic inflammation contributes to obesity-associated complications. The short pentraxin C-reactive protein (CRP) is a validated inflammatory marker, whereas long pentraxin-3 (PTX3) limits inflammation and is adaptively stimulated by proinflammatory cytokines in vitro. Severely obese (SO) patients (body mass index [BMI]>40] have the highest obesity-associated complications and increasingly undergo surgical treatment. SO-associated changes in plasma PTX3 and their interactions with systemic inflammation are, however, unknown. OBJECTIVE: We sought to determine potential alterations in plasma PTX3 and their associations with changes in inflammatory markers before and after weight loss induced by laparoscopic Roux-en-Y gastric bypass (LRYGB). SETTING: University hospital in Trieste, Italy. METHODS: Plasma PTX3, CRP, and cytokines, including tumor necrosis factor α and interleukin 6 were measured in (1) 24 individuals with severe, class III obesity (SO; age = 42 ± 1 yr, female/male = 18/6, BMI = 45 ± 1 kg/m(2)) before and 3, 6, and 12 months after LRYGB; and (2) age- and sex-matched normal-weight (N; n = 56, BMI = 22 ± .2 kg/m(2)) or class I obese individuals (O; n = 44, BMI = 31.2 ± .3 kg/m(2)). RESULTS: SO, but not O, had higher plasma PTX3 compared with N, associated with highest proinflammatory cytokines and CRP (P<.05 versus N-O). In all patients, plasma interleukin 6 and tumor necrosis factor α were associated positively with PTX3 (P<.05). Plasma CRP and proinflammatory cytokines declined during LRYGB-induced weight loss. In contrast, high PTX3 further increased and remained elevated (P<.05 versus basal). CONCLUSIONS:Obesity level and energy balance modulate interactions between PTX3 and systemic inflammation. Elevated PTX3 is a novel, potentially adaptive alteration associated with proinflammatory cytokines in SO. Their differential changes conversely suggest circulating PTX3 as a novel negative inflammatory marker in SO undergoing LRYGB-induced weight loss.
Authors: Edward P Weiss; Dominic N Reeds; Uthayashanker R Ezekiel; Stewart G Albert; Dennis T Villareal Journal: Endocrine Date: 2016-09-07 Impact factor: 3.633
Authors: G Rega-Kaun; C Kaun; G Jaegersberger; M Prager; M Hackl; S Demyanets; J Wojta; P J Hohensinner Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: David J Lederer; Jason D Christie; Joshua M Diamond; Selim Arcasoy; Jamiela A McDonnough; Joshua R Sonett; Matthew Bacchetta; Frank D'Ovidio; Edward Cantu; Christian A Bermudez; Amika McBurnie; Melanie Rushefski; Laurel H Kalman; Michelle Oyster; Carly D'Errico; Yoshikazu Suzuki; Jon T Giles; Anthony Ferrante; Matthew Lippel; Gopal Singh Journal: Am J Transplant Date: 2016-08-18 Impact factor: 8.086
Authors: P J Hohensinner; C Kaun; B Ebenbauer; M Hackl; S Demyanets; D Richter; M Prager; J Wojta; Gersina Rega-Kaun Journal: Obes Surg Date: 2018-09 Impact factor: 4.129
Authors: Katarzyna Wyskida; Grzegorz Franik; Piotr Choręza; Natalia Pohl; Leszek Markuszewski; Aleksander Owczarek; Paweł Madej; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz Journal: Int J Endocrinol Date: 2020-09-02 Impact factor: 3.257